Stock Events

Stock Events

Enanta Pharmaceuticals 

$12.78
15
-$0.17-1.31% Friday 20:00
+$0.00+0%Friday 20:01After hours

Statistics

Day High
12.78
Day Low
12.74
52W High
16.85
52W Low
6.49
Volume
2,400
Avg. Volume
-
Mkt Cap
371.62M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-1.35
-1.04
-0.73
-0.42
Expected EPS
-0.509507
Actual EPS
N/A

Financials

-125.36%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
65.32MRevenue
-81.89MNet Income

Analyst Ratings

20.00Average Price Target
The highest estimate is 20.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENTA. It's not an investment recommendation.
AT&T
6
T
Microsoft
5
MSFT
Johnson & Johnson
5
JNJ
PepsiCo
5
PEP

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences is a direct competitor in the antiviral drug market, particularly in treatments for hepatitis C, where Enanta and Gilead have had collaborations but also compete.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie competes with Enanta in the hepatitis C virus (HCV) treatment market, especially since Enanta has developed drugs that are part of AbbVie's HCV treatment regimens.
Merck
MRK
Mkt Cap305.12B
Merck & Co. is involved in developing treatments for infectious diseases, including hepatitis C, directly competing with Enanta's drug development focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals competes with Enanta in the development of treatments for cystic fibrosis, as both companies are involved in creating therapies for genetic and chronic diseases.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb competes in the antiviral space, particularly in hepatitis B and C, areas where Enanta Pharmaceuticals has significant interest and development efforts.
Pfizer
PFE
Mkt Cap137.76B
Pfizer competes across a broad range of therapeutic areas, including antiviral drugs, which puts it in competition with Enanta Pharmaceuticals in the infectious disease market.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson, through its pharmaceutical division Janssen, competes with Enanta in the development of treatments for infectious diseases, including hepatitis C.
GSK
GSK
Mkt Cap105.71B
GlaxoSmithKline competes with Enanta in the development of vaccines and treatments for viral infections, including hepatitis and respiratory diseases.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap10.76B
Arrowhead Pharmaceuticals is involved in developing RNAi therapeutics for chronic diseases, including hepatitis B, making it a competitor in the viral infection treatment market.

About

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Show more...
CEO
Dr. Jay R. Luly Ph.D.
Employees
120
Country
United States
ISIN
US29251M1062

Listings

MU
DE
9EP.MU
STU
DE
9EP.STU
F
DE
9EP.F
XNAS
US
ENTA

0 Comments

Share your thoughts

FAQ

What is Enanta Pharmaceuticals stock price today?▼
The current price of ENTA is $12.78 USD — it has decreased by -1.31% in the past 24 hours. Watch Enanta Pharmaceuticals stock price performance more closely on the chart.
What is Enanta Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Enanta Pharmaceuticals stocks are traded under the ticker ENTA.
Is Enanta Pharmaceuticals stock price growing?▼
ENTA stock has fallen by -6.99% compared to the previous week, the month change is a -8.71% fall, over the last year Enanta Pharmaceuticals has showed a +72.7% increase.
What is Enanta Pharmaceuticals market cap?▼
Today Enanta Pharmaceuticals has the market capitalization of 371.62M
When is the next Enanta Pharmaceuticals earnings date?▼
Enanta Pharmaceuticals is going to release the next earnings report on August 10, 2026.
What were Enanta Pharmaceuticals earnings last quarter?▼
ENTA earnings for the last quarter are -0.45 USD per share, whereas the estimation was -0.49 USD resulting in a +7.66% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Enanta Pharmaceuticals revenue for the last year?▼
Enanta Pharmaceuticals revenue for the last year amounts to 65.32M USD.
What is Enanta Pharmaceuticals net income for the last year?▼
ENTA net income for the last year is -81.89M USD.
How many employees does Enanta Pharmaceuticals have?▼
As of July 26, 2026, the company has 120 employees.
In which sector is Enanta Pharmaceuticals located?▼
Enanta Pharmaceuticals operates in the Health & Wellness sector.
When did Enanta Pharmaceuticals complete a stock split?▼
Enanta Pharmaceuticals has not had any recent stock splits.
Where is Enanta Pharmaceuticals headquartered?▼
Enanta Pharmaceuticals is headquartered in Watertown, United States.